Evidence map›Paper›PMID 42520384›Full record

ArticleRedox biology2026

Deoxycholic acid impairs mitochondrial fitness and suppresses mitophagy through Parkin ubiquitination driving CD8

Yang Gao, Jiaxin Wang, Shihui Lai, Mingwei Li, Jiaqi Shi, Xianjun Li, Ying Guo, Sainan Ma, Xinxin Wang, Shule Zhang and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Redox biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Yang GaoHeilongjiang Province Key Laboratory of Molecular Oncology, Harbin, Heilongjiang, China; Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Jiaxin WangHeilongjiang Province Key Laboratory of Molecular Oncology, Harbin, Heilongjiang, China.
Shihui LaiHeilongjiang Province Key Laboratory of Molecular Oncology, Harbin, Heilongjiang, China; Department of Hepatobiliary and Pancreatic Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
Mingwei LiHeilongjiang Province Key Laboratory of Molecular Oncology, Harbin, Heilongjiang, China; Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Jiaqi ShiHeilongjiang Province Key Laboratory of Molecular Oncology, Harbin, Heilongjiang, China; Department of Phase I Trials Center, Harbin Medical University Cancer Hospital, Harbin, China.
Xianjun LiHeilongjiang Province Key Laboratory of Molecular Oncology, Harbin, Heilongjiang, China; Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China; Heilongjiang Cancer Institute, Harbin, China.
Ying GuoHeilongjiang Province Key Laboratory of Molecular Oncology, Harbin, Heilongjiang, China.
Sainan MaHeilongjiang Province Key Laboratory of Molecular Oncology, Harbin, Heilongjiang, China; Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Xinxin WangImaging Department, Harbin Medical University Cancer Hospital, Harbin, China.
Shule ZhangState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
Tianyu HeState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
Yu HongJiangsu Provincial Key Laboratory of Targetome and Innovative Drugs, Institute of Innovative Drug, China Pharmaceutical University, Nanjing, China.
Shuang LiHeilongjiang Province Key Laboratory of Molecular Oncology, Harbin, Heilongjiang, China; Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China. Electronic address: drlishuang@hrbmu.edu.cn.
Caiqi LiuHeilongjiang Province Key Laboratory of Molecular Oncology, Harbin, Heilongjiang, China; Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China. Electronic address: liucaiqi@ems.hrbmu.edu.cn.
Lijuan CaoState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China; Jiangsu Provincial Key Laboratory of Targetome and Innovative Drugs, Institute of Innovative Drug, China Pharmaceutical University, Nanjing, China. Electronic address: caolijuan0702@cpu.edu.cn.
Haiping HaoState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China; Laboratory of Metabolic Regulation and Drug Target Discovery, School of Pharmacy, China Pharmaceutical University, Nanjing, China. Electronic address: haipinghao@cpu.edu.cn.
Chujie DingHeilongjiang Province Key Laboratory of Molecular Oncology, Harbin, Heilongjiang, China; Scientific Research Center, Harbin Medical University Cancer Hospital, Harbin, China. Electronic address: dingchujie@hrbmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) exhibits significant heterogeneity in response to immunotherapy that cannot be fully explained by microsatellite status alone. Although elevated bile acid levels are recognized as an important risk factor for CRC, their impact on immunotherapy responsiveness remains poorly understood. Here, we demonstrate that high bile acid levels profoundly impair anti-PD-1 efficacy in both CRC patient cohort and mouse models, accompanied by reduced infiltration and functional impairment of tumor-infiltrating CD8

Indexed as

CD8-Positive T-LymphocytesColorectal NeoplasmsDeoxycholic AcidMitochondriaMitophagyUbiquitin-Protein LigasesAnimalsCell Line, TumorHumansMiceReactive Oxygen SpeciesT-Cell ExhaustionUbiquitinationDeoxycholic Acidparkin proteinReactive Oxygen SpeciesUbiquitin-Protein LigasesAnti-PD-1 therapyCD8(+) T cell terminal exhaustionColorectal cancerDeoxycholic acidMitochondrial dysfunctionMitophagy

Identifiers

PMID42520384
PMCPMC13450440

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.